TIM-3, a promising target for cancer immunotherapy.
TIM-3, a promising target for cancer immunotherapy.
复制标题
DOI：
10.2147/ott.s170385
复制
发表时间：
2018
影响因子：
4
通讯作者：
Hirsch FR
中科院分区：
文献类型：
--
作者：
He Y;Cao J;Zhao C;Li X;Zhou C;Hirsch FR
多年来，恶性肿瘤患者接受免疫治疗已获得显著的临床益处。免疫检查点阻断剂，如抗细胞毒性T淋巴细胞相关蛋白-4（anti-CTLA-4）和抗程序性细胞死亡蛋白-1（anti-PD-1）单克隆抗体，在不同类型的癌症中产生了令人印象深刻的临床结果。T细胞免疫球蛋白和粘蛋白结构域3（TIM-3），另一个免疫检查点，可以抑制癌症免疫。最近的研究强调TIM-3在T细胞耗竭中起重要作用，并与抗PD-1治疗的结果相关。靶向TIM-3可能是一种有前途的癌症免疫治疗方法。在这里，我们回顾了TIM-3在癌症中的作用以及TIM-3抑制剂的临床试验。
Patients with malignant tumor treated with immunotherapy have received significant clinical benefits over the years. Immune checkpoint blocking agents, such as anti-cytotoxic T-lymphocyte-associated protein-4 (anti-CTLA-4) and anti-programmed cell death protein-1 (anti-PD-1) monoclonal antibodies, have produced impressive clinical results in different types of cancer. T-cell immunoglobulin and mucin domain-3 (TIM-3), another immune checkpoint, could inhibit cancer immunity. Recent studies have highlighted that TIM-3 has an important role to play in T-cell exhaustion and correlates with the outcome of anti-PD-1 therapy. Targeting TIM-3 might be a promising approach for cancer immunotherapy. Here, we review the role of TIM-3 in cancer and clinical trials with TIM-3 inhibitors.